Suprachoroidal Internal Development Pipeline

Study drug

Indication

Current Status

CLS-AX
(axitinib injectable suspension)
Wet AMD row1

Integrin Inhibitor

(Injectable suspension)

Diabetic Macular Edema (DME)

row3

Gene Therapy: Extracellular protein

“Therapeutic Biofactory

row3

Gene Therapy: Intracellular protein

Inherited Retinal Disease

row3

Development and Commercial Programs using SCS Microinjector®

Partner 

Indication

Current Status

REGENXBIO

Wet AMD (AAVIATE)

row1

REGENXBIO

Diabetic Retinopathy (ALTITUDE)

row1

AURA BIOSCIENCES

Ocular Oncology / 
Choroidal Melanoma

row1

XIPERE™ Commercial Licenses

Partner 

Indication

Current Status

BAUSCH HEALTH

U.S. & Canada; options outside
North America

row1

ARCTIC VISION

Greater China & South Korea

row1

XIPERE™ is an investigational product | XIPERE licenses: Bausch Health – U.S. and Canada; Arctic Vision – Greater China and South Korea